CoChat

Scaling up Xpert MTB/RIF technology: the costs of laboratory‐ vs. clinic‐based roll‐out in South Africa

Open access
Schnippel, Kathryn, Meyer‐Rath, Gesine, Long, Lawrence, MacLeod, William, Sanne, Ian, Stevens, Wendy S., Rosen, Sydney · 2012 · Tropical Medicine & International Health
Cited by 54

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Objective The World Health Organization recommends using Xpert MTB/RIF for diagnosis of pulmonary tuberculosis (PTB), but there is little evidence on the optimal placement of Xpert instruments in public health systems. We used recent South African data to compare the cost of placing Xpert at points of TB treatment (all primary clinics and hospitals) with the cost of placement at sub‐district laboratories. Methods We estimated Xpert’s cost/test in a primary clinic pilot and in the pilot phase of the national Xpert roll‐out to smear microscopy laboratories; the expected future volumes for each of 223 laboratories or 3799 points of treatment; the number and cost of Xpert instruments required and the national cost of using Xpert for PTB diagnosis for each placement scenario in 2014. Results In 2014, South Africa will test 2.6 million TB suspects. Laboratory placement requires 274 Xpert instruments, while point‐of‐treatment placement requires 4020 instruments. With an Xpert cartridge price of $14.00, the cost/test is $26.54 for laboratory placement and $38.91 for point‐of‐treatment placement. Low test volumes and a high number of sites are the major contributors to higher point‐of‐treatment costs. National placement of Xpert at laboratories would cost $71 million/year; point‐of‐treatment placement would cost $107 million/year, 51% more. Conclusion Placing Xpert technology at points of treatment is substantially more expensive than placing the instruments in smear microscopy laboratories. The incremental benefits of point‐of‐treatment placement, in terms of better patient outcomes, will have to be equally substantial to justify the additional cost to the national health budget.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-3156.2012.03028.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Rapid Molecular Detection of Tuberculosis and Rifampin Resistance

    Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 2×

    “The Xpert MTB ⁄ RIF (Xpert) assay for the GeneXpert (GX) platform (Cepheid, Sunnyvale, CA, USA), which provides both rapid and specific detection of Mycobacterium tuberculosis (MTB) and identification of rifampicin (RIF) drug resistance, is seen as one promising solution to this problem (Boehme et al. 2010; Helb et al…”
    BackgroundMethod
  • Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology

    Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914 · cited 3×

    “Early reports on the Xpert MTB ⁄ RIF technology suggest that it was designed to be placed at patient-contact sites where nurses could provide treatment immediately upon diagnosis (Helb et al. 2010; Morris 2010; Boehme et al. 2011).”
    BackgroundMethod
  • Xpert MTB/RIF: a New Pillar in Diagnosis of Extrapulmonary Tuberculosis?

    Vadwai, V., Boehme, C., Nabeta, P., Shetty, A., Alland, D., & Rodrigues, C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02319-10 · Cited by 357 · cited 2×

    “Adjustments made to current volumes to exclude smears for diagnosing EPTB may underestimate the volume of Xpert tests that will be required if Xpert becomes the diagnostic of choice for EPTB (Vadwai et al. 2011) and ⁄ or paediatric TB (Nicol et al. 2011) as well.”
    Background

Cited by

See all 54

Metadata

Authors
Schnippel, K., Meyer‐Rath, G., Long, L., MacLeod, W., Sanne, I., Stevens, W. S., & Rosen, S.
Venue
Tropical Medicine & International Health
Publisher
Wiley
Published
2012-06-12
Volume
17
Issue
9
Pages
1142-1151
ISSN
  • 1360-2276 (ISSN-L)
  • 1365-3156
OpenAlex
W1652831512
Cited by
54
References
3
FWCI
4.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.